Combined immunotherapy (anti-PD-L1 and CTLA-4) for aggressive pituitary adenomas is still in phase 2 (Memorial Sloan Kettering cancer center, United States, NCT04042753). This evidence concerns the gene CTLA4 and pituitary gland adenoma.